Monday, January 23, 2023 Daily Archives

Host Cell Proteins — Bench to Production Solutions

by

Enzyme-linked immunosorbent assays (ELISA) are commonly used in analytical chemistry. They can be used in process development for biologic therapies to detect and quantitate host cell protein (HCP) contamination. HCP can cause immunogenic responses in patients and reduce efficacy of these therapies and therefore must be removed to meet regulatory requirements. Some challenges you may run into when utilizing ELISAs are how to prepare your samples, choosing the best generic/commercial ELISA for your needs, and ensuring security of supply for…

January 23, 2023

CDMO GenScript ProBio raises $224m

by

GenScript ProBio of Nanjing, a biologics CDMO with operations around the globe, has raised $224 million in a C round funding. ProBio offers end-to-end contract development and manufacturing organization (CDMO) services from drug discovery to commercialization for antibodies, cell and gene therapies. The company said it would use the capital to increase manufacturing capacity, advance its R&D offerings and acquire companies that add services. After the funding, GenScript Biotech, a gene synthesis company, will continue to own 70% of ProBio,…

January 23, 2023

WuXi ATU wins tech disruptor at #ATW awards in Miami

by

A transfection-free and scalable AAV technology has bagged WuXi ATU the Manufacturing Tech Disruptor of the Year Award at the first Advanced Therapies Awards ceremony. Miami, Florida’s famous Fontainebleau Hotel hosted the integral Advanced Therapies Week (ATW) Awards event last week, honoring progress and success in cell and gene therapies. Highlights of the evening including the presentation of the Lifetime Achievement Award to Carl June – the cell therapy pioneer and Time Magazine ‘Person of the Year’ runner-up 2016, who…

January 23, 2023

Normax and MTIF take mRNA tech to UK Uni

by

Normax Biomed has partnered with Medical Technologies Innovation Facility (MTIF) at Nottingham Trent University (NTU) to provide access to Telesis Bio’s BioXP system. The agreement, of which financial details have not been divulged, will see NTU develop and discover gene therapies and messenger RNA (mRNA) vaccines using the BioXP system. Irish mRNA-based company Normax claims the BioXP platform, created by Californian firm Telesis Bio, is the world’s first commercially available end-to-end fully automated bench top synthetic biology system . The…

January 23, 2023